__NUXT_JSONP__("/drugs/Nurulimab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"2168561-20-2",chebiId:b,chemicalFormula:b,definition:"A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.",fdaUniiCode:"894KSI08XK",identifier:"C156734",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C128036","C129822"],synonyms:["Anti-CTLA-4 Monoclonal Antibody BCD-145","BCD 145","BCD-145","BCD145","NURULIMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNurulimab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Nurulimab","","2021-10-30T13:34:27.853Z")));